Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: secor002@mc.duke.edu

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994

Certifications

  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011

Research

Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 

 

Selected Grants and Awards

Publications

Berchuck, A., A. A. Secord, L. J. Havrilesky, R. Wenham, J. T. Soper, and D. L. Clarke-Pearson. “Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer..” In Journal of Clinical Oncology, 22:487S-487S. AMER SOC CLINICAL ONCOLOGY, 2004.

Scholars@Duke

Secord, A. A., E. Jones, C. A. Hahn, L. J. Havrilesky, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, and L. R. Prosnitz. “Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer..” In Journal of Clinical Oncology, 22:471S-471S. AMER SOC CLINICAL ONCOLOGY, 2004.

Scholars@Duke

Berchuck, A., A. A. Secord, L. J. Havrilesky, R. Wenham, J. T. Soper, and D. L. Clarke-Pearson. “Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).

Scholars@Duke

Secord, A. A., E. Jones, C. A. Hahn, L. J. Havrilesky, J. T. Soper, A. Berchuck, D. L. Clarke-Pearson, L. R. Prosnitz, and M. W. Dewhirst. “Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004).

Scholars@Duke

Alvarez Secord, Angeles, Robyn Sayer, Stacey A. Snyder, Gloria Broadwater, Gustavo C. Rodriguez, Andrew Berchuck, and Kimberly Blackwell. “The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer..” Gynecologic Oncology 94, no. 1 (July 2004): 74–79. https://doi.org/10.1016/j.ygyno.2004.03.043.

Full Text

Moller, Karen A., Paola A. Gehrig, Linda Van Le, Angeles Alvarez Secord, and John Schorge. “The role of optimal debulking in advanced stage serous carcinoma of the uterus..” Gynecologic Oncology 94, no. 1 (July 2004): 170–74. https://doi.org/10.1016/j.ygyno.2004.03.040.

Full Text

Havrilesky, Laura J., Charles A. Leath, Warner Huh, Brian Calingaert, Rex C. Bentley, John T. Soper, and Angeles Alvarez Secord. “Radical hysterectomy and pelvic lymphadenectomy for stage IB2 cervical cancer..” Gynecol Oncol 93, no. 2 (May 2004): 429–34. https://doi.org/10.1016/j.ygyno.2004.01.038.

Full Text

Berchuck, A., A. A. Alvarez, and J. E. Stout. “Abdominal pain and bloating in two 20-something patients.” Contemporary Ob/Gyn 48, no. 1 (December 1, 2003): 51–58.

Scholars@Duke

Roth, Ted M., Angeles Alvarez Secord, Laura J. Havrilesky, Ellen Jones, and Daniel L. Clarke-Pearson. “High dose rate intraoperative radiotherapy for recurrent cervical cancer and nodal disease..” Gynecologic Oncology 91, no. 1 (October 2003): 258–60. https://doi.org/10.1016/s0090-8258(03)00443-8.

Full Text

Pages